Salamol Inhaler
Salamol CFC-Free Inhaler contains salbutamol sulphate, a fast-acting bronchodilator that provides quick relief from asthma symptoms by opening up the airways in the lungs. This reliever inhaler works within minutes and its effects last for 4-6 hours. It is used to treat asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Salamol can be used both to prevent asthma symptoms before they occur and to relieve symptoms once they start.
Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £8.86 via Klarna
Tracked 24 Delivery3 interest-free payments via KlarnaDiscreet packaging
Salamol Treatment
| Product Name | Salamol |
| Manufacturer | IVAX Pharmaceuticals Ireland |
| Active Ingredient | Salbutamol Sulphate |
| Administration | Oral Inhalation |
| Presentation | Pressurised Inhalation Suspension |
| Available Strengths | 100 micrograms/puff / 200 doses |
| Product Type | POM — Prescription Only |
| Dosage | Inhale ONE or TWO puffs when needed for wheeze or breathlessness, up to FOUR times in 24 hours. Seek urgent help if symptoms are not relieved. |
| Suitable for pregnancy? | Caution |
| Use with alcohol | Yes |
| Link to Patient Information Leaflet | Salamol PIL ↗ |
Medical Content Officer
Nabeel is a co-founder, and medical content officer of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Talal is a GMC registered doctor and medical content reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.
Medical Administrative Officer
Usman is a co-founder, and medical administrative officer of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical administration and operational priorities.
Review Date: 2 Jul 2026
Next Review: 1 Jan 2027
Published on: 19 Nov 2025
Last Updated: 3 Jul 2026
